ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 9ÔÂ18ÈÕ£¬£¬£¬Åµ»ª£¨Novartis£©Ðû²¼£¬£¬£¬ÃÀ¹úFDAÒÑÅú×¼CDK4/6ÒÖÖÆ¼ÁKisqali£¨ribociclib£©ÁªºÏ·¼ÏãøÒÖÖÆ¼Á£¨AI£©£¬£¬£¬×÷Ϊ¸ß¸´·¢Î£º¦µÄ¼¤ËØÊÜÌåÑôÐÔ/ÈË±íÆ¤Éú³¤Òò×ÓÊÜÌå2ÒõÐÔ£¨HR+/HER2-£©IIÆÚºÍIIIÆÚÔçÆÚÈéÏÙ°©£¨EBC£©»¼Õߵĸ¨ÖúÖÎÁÆ£¬£¬£¬°üÀ¨ÎÞÁÜͶºÏ×ªÒÆ£¨N0£©µÄ»¼Õß¡£¡£¡£¡£¡£¡£
2. 9ÔÂ18ÈÕ£¬£¬£¬¾ÝCDE¹ÙÍøÐÂÎÅ£¬£¬£¬ËÕÖÝÐÅŵάҽҩ¿Æ¼¼¹É·ÝÓÐÏÞ¹«Ë¾ÁªºÏÉêÇëÒ©Æ·¡°×¢ÉäÓÃÑǰ·ÅàÄÏÎ÷˾Ëû¶¡ÄƸ£Åµ°Í̹¡±£¬£¬£¬»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬Ë³Ó¦Ö¢£º±¾Æ·ÊÊÓÃÓÚ 18 Ëê¼°ÒÔÉϵϼÕߣ¬£¬£¬ÖÎÁÆÓɶԱ¾Æ·Ãô¸ÐµÄ¸ïÀ¼ÒõÐÔ¾ú£¬£¬£¬°üÀ¨±«Âü²»¶¯¸Ë¾ú£¬£¬£¬´ó³¦¸Ë¾ú£¨Èç·ÎÑ׿ËÀײ®¸Ë¾ú£¬£¬£¬´ó³¦°£Ï£¾ú£©£¬£¬£¬ÍÂ̼ٵ¥°û¾úÒýÆðµÄÒÔÏÂѬȾ£ºÒ½Ôº»ñµÃÐÔϸ¾úÐÔ·ÎÑ׺ͺôÎü»úÏà¹ØÐÔϸ¾úÐÔ·ÎÑ×£¨HABP/VABP£©¡£¡£¡£¡£¡£¡£
3. 9ÔÂ18ÈÕ£¬£¬£¬¿ÆÂ×Ò©ÒµÐû²¼Í¨¸æ£¬£¬£¬¹«Ë¾»¯Ñ§Ò©Æ·µØÇüÔÐͪƬÓÚ¿ËÈÕ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖµÄÒ©Æ·×¢²áÅú×¼¡£¡£¡£¡£¡£¡£µØÇüÔÐͪƬΪÑÅÅ࿪·¢£¬£¬£¬ÓÃÓÚÖÎÁÆÄÚÔ´ÐÔÔÐͪȱ·¦ÒýÆðµÄÏà¹Ø¼²²¡£¡£¡£¡£¡£¡£¬£¬£¬ÈçÍ´¾¡¢×Ó¹¬ÄÚĤÒìλ֢¡¢Ôм¤ËØÈ±·¦ËùÖÂÏÈÕ×ÐÔÁ÷²ú»òϰ¹ßÐÔÁ÷²ú¼°¸¨ÖúÉúÖ³¼¼ÊõÖеĻÆÌåÖ§³ÖµÈ¡£¡£¡£¡£¡£¡£
4. 9ÔÂ18ÈÕ£¬£¬£¬Ðû̩ҽҩͨ¸æ£¬£¬£¬¹«Ë¾Ïò¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÉ걨µÄ´ï¸ñÁо»¶þ¼×Ë«ëÒ»ºÊÍÆ¬²úÆ·ÒÑ»ñµÃÕýʽÅú×¼£¬£¬£¬Îª¸ÃÆ·ÖÖº£ÄÚÊ×¼Ò»ñÅúµÄ·ÂÖÆÒ©¡£¡£¡£¡£¡£¡£´ï¸ñÁо»¶þ¼×Ë«ëÒ»ºÊÍÆ¬ÓÃÓÚÖÎÁÆ2ÐÍÌÇÄò²¡¡£¡£¡£¡£¡£¡£
1. 9ÔÂ17ÈÕ£¬£¬£¬Ò»¼Ò¿ª·¢ÓÃÓÚÖÎÁÆÓÐÊý¼²²¡µÄת»¯Ï¸°ûºÍÍâÃÚÌåÁÆ·¨µÄÉúÎï¼¼Êõ¹«Ë¾Capricor Therapeutics Ðû²¼ÒÑÓëÈÕ±¾ÐÂÒ©Öêʽ»áÉç¾ÍÇ©ÊðÁ˾ßÓÐÔ¼ÊøÁ¦µÄÌõ¿îÇåµ¥¡£¡£¡£¡£¡£¡£Ìõ¿îÌåÏÖ£¬£¬£¬ÈÕ±¾ÐÂÒ©Öêʽ»áÉ罫ÔÚÅ·ÖÞÉÌÒµ»¯ºÍ·ÖÏú Capricor µÄÖ÷Òª×ʲú deramiocel£¬£¬£¬ÓÃÓÚÖÎÁƶÅÊϼ¡ÓªÑø²»Á¼Ö¢ (DMD)¡£¡£¡£¡£¡£¡£Capricor ½«ÒÔ 20% µÄÒç¼Û»ñµÃ 1500 ÍòÃÀÔªµÄ¹ÉȨͶ×Ê£¬£¬£¬²¢ÔÚÇ©Êð×îÖÕÐÒéºó»ñµÃ 2000 ÍòÃÀÔªµÄÔ¤¸¶¿î£¬£¬£¬ÆäÖÐDZÔÚÀï³Ì±®½ð¶î¸ß´ï 7.15 ÒÚÃÀÔª£¬£¬£¬²úÆ·ÊÕÈëÕ¼±ÈµÖ´ïÁ½Î»Êý£¬£¬£¬×ۺϷÖÏúÐÒéµÄDZÔÚÀï³Ì±®ÏÖÔÚ×ܶîԼΪ 15 ÒÚÃÀÔª¡£¡£¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬À´×ÔÓ¢¹ú½£ÇÅ´óѧµÄMasashi NaritaÍŶÓÓÚNatureÉÏÔÚÏß½ÒÏþÌâΪTitration of RAS alters senescent state and influences tumour initiationµÄÎÄÕ£¬£¬£¬Í¨¹ýÌåÍâºÍÌåÄÚÄ£×Ó£¬£¬£¬Õ¹ÏÖÁËRAS»ùÒò¼ÁÁ¿µÝÔö¶ÔÖ×ÁöÉú³¤µÄÓ°Ï죬£¬£¬·¢Ã÷NRAS (G12V)±í ´ïˮƽÓë¸Îϸ°ûOIS±íÐͺÍÖ×ÁöÃâÒßɨ³ýÓйأ¬£¬£¬Ö¤Êµ²î±ðNRAS (G12V) ˮƽµ¼Ö²î±ðÖ×ÁöÀàÐÍ£¬£¬£¬ÓëÈËÀà¸Îϸ°û°©£¨HCC£©ÑÇÀàÏà¹Ø£¬£¬£¬ÖØÐ½ç˵ÁËÓÉÖ°©¼ÁÁ¿Çý¶¯µÄOISÆ×ϵ£¬£¬£¬Ðµ÷ÁËÔçÆÚÖ×Áö±¬·¢ÖеÄÐàÂõºÍÖ×Áö±¬·¢±íÐÍ¡£¡£¡£¡£¡£¡£
[1] Chan, A.S.L., Zhu, H., Narita, M. et al. Titration of RAS alters senescent state and influences tumour initiation. Nature (2024). https://doi.org/10.1038/s41586-024-07797-z
Ïà¹ØÐÂÎÅ